<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> is the most common cause of <z:hpo ids='HP_0001892'>bleeding tendency</z:hpo> and, if due to impaired platelet production, is best treated by platelet transfusion </plain></SENT>
<SENT sid="1" pm="."><plain>For patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> prophylactic platelet transfusion should be considered if platelet count is below 20 x 10(9)/l </plain></SENT>
<SENT sid="2" pm="."><plain>This will be underlined by a retrospective analysis at our clinic of 231 patients suffering from <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> <z:e sem="disease" ids="C0026998" disease_type="Neoplastic Process" abbrv="">FAB M1</z:e>-7) and showing an early-<z:hpo ids='HP_0011420'>death</z:hpo> rate of 7.7% by <z:mp ids='MP_0001914'>bleeding</z:mp> complications </plain></SENT>
<SENT sid="3" pm="."><plain>To estimate the effectiveness of platelet transfusions, not only stopping of <z:mp ids='MP_0001914'>bleeding</z:mp> symptoms and corrected count increment (CCI) should be taken into account but also whether the patient has <z:hpo ids='HP_0001945'>fever</z:hpo>, <z:hpo ids='HP_0100806'>sepsis</z:hpo>, hepato-<z:hpo ids='HP_0001744'>splenomegaly</z:hpo> or has taken special drugs </plain></SENT>
<SENT sid="4" pm="."><plain>Measuring the in vivo <z:mp ids='MP_0001914'>bleeding</z:mp> time is of little use for low reproduction and is stressing for patients </plain></SENT>
<SENT sid="5" pm="."><plain>In 1985 Kratzer described a new and sensitive method for the evaluation of platelet function </plain></SENT>
<SENT sid="6" pm="."><plain>After modifying this method it is now possible to test platelet function even with platelet counts below 50 x 10(9)/l </plain></SENT>
</text></document>